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Leukocyte inﬁltration across an activated brain endothelium contributes to the neuroinﬂammation seen in many neurological
disorders. Recent evidence shows that IL-17-producing T-lymphocytes (e.g., Th17 cells) possess brain-homing capability and
contribute to the pathogenesis of multiple sclerosis and cerebral ischemia. The leukocyte transmigration across the endothelium
is a highly regulated, multistep process involving intercellular communications and interactions between the leukocytes and
endothelial cells. The molecules involved in the process are attractive therapeutic targets for inhibiting leukocyte brain migration.
We hypothesized and have been successful in demonstrating that molecules of potential therapeutic signiﬁcance involved in
Th17-brain endothelial cell (BEC) communications and interactions can be discovered through the combination of advanced
membrane/submembrane proteomic and interactomic methods. We describe elements of this strategy and preliminary results
obtained in method and approach development. The Th17-BEC interaction network provides new insights into the complexity
of the transmigration process mediated by well-organized, subcellularly localized molecular interactions. These molecules and
interactions are potential diagnostic, therapeutic, or theranostic targets for treatment of neurological conditions accompanied or
caused by leukocyte inﬁltration.
1.LeukocyteInﬁltrationinCNSDisorders
The central nervous system (CNS)has long been regarded as
an “immune privileged” organ, being both immunologically
inert and immunologically separated from the peripheral
immune system [1]. Current data, however, indicates that
the CNS is both immune competent and actively interactive
with the peripheral immune system [2]. In physiological
conditions, a limited number of peripheral immune cells
cross the blood-brain barrier (BBB) and enter the CNS in a
processcalled“immune surveillance”[1].Many neurological
diseases are associated with a much higher rate of leukocyte
traﬃcking into the CNS, resulting in leukocyte inﬁltration
and leukocyte-mediated neuronal damage. CNS inﬂamma-
tion is a major contributor to the diverse forms of brain
injury seen in cerebral ischemia, multiple sclerosis, cerebral
infection, and epilepsy [3–5].
Agrowing body ofrecentevidenceshows thatinﬁltration
of a subset of IL-17-producing T-lymphocytes into the
CNS contributes to the pathogenesis of multiple sclerosis,
and cerebral ischemia. In multiple sclerosis these cells are
CD4+ T helper 17 (Th17) lymphocytes that have CNS-
homing properties and mediate the immune response
directed at the myelin sheath. Gyulveszi and coworkers
recently demonstrated that the CNS tropism of Th17 cells
is driven by IL23, since T cells defective in IL-23 signaling
fail to accumulate in the CNS in the mouse model of
experimental autoimmune encephalomyelitis (EAE) [6].
These ﬁndings are consistent with the report by Prat and
colleagues,showing thatIL-23-stimulatedTh17lymphocytes
promote BBB disruption in vitro and in the EAE, eﬃciently
penetrate the BBB, kill neurons, and promote further
CNS inﬂammation through CD4+ lymphocyte recruitment
[7].2 Cardiovascular Psychiatry and Neurology
In experimental ischemic stroke, T-lymphocytes are lo-
calized to the infarction boundary zones [8] and contribute
to the development of secondary inﬂammatory brain injury
[9]. More recently, Shichita et al. have shown that in mice
subjected to a transient middle cerebral artery occlusion
an initial inﬁltration of IL-23-producing macrophages is
followed by subsequent recruitment/activation of IL-17-
producing γδTl y m p h o c y t e s[ 10]. These T cells concomi-
tantlyincreasedownstreamproinﬂammatoryandneurotoxic
factors and the infarct size after focal cerebral ischemia
[10]. Thus, as in multiple sclerosis, IL17-producing T cells
activated by IL-23 are believed to “home-in” towards the
CNS and induce injury during cerebral stroke.
2.MolecularMechanisms ofLeukocyte
Migrationthroughthe EndothelialLayer
The endothelial lining of brain capillaries exhibits a special-
ized phenotype, commonly referred to as the blood-brain
barrier (BBB). These endothelial cells (ECs) function as a
restrictive gate to control the composition of extracellular
ﬂuidinthecentralnervoussystem(CNS),selectivelyrestrict-
ing and/or controlling the access of blood-borne molecules
to the brain [11]. The brain capillary endothelium exhibits
unique anatomical and biochemical features, including tight
junctions (TJ) that form a physical barrier for a majority
of hydrophilic molecules larger than 500Da, low pinocytic
activity, and the polarized expression of transporters that
control both brain inﬂux and eﬄux of molecular substrates
[11].
The luminal surface of BEC (i.e., the side accessible to
the blood) contains a thick glycocalyx, which is enriched in
proteins and glycoproteins involved in key BBB functions,
including the transport of solutes and macromolecules,
BEC permeability, vasoreactivity, and interactions with cir-
culating cells and platelets [12–15]. Under inﬂammatory
conditions, luminal adhesion molecules in the glycocalyx
directly interact with leukocytesduring the highly-regulated,
multistep transmigration process involving tethering and
rolling,activation,arrest,anddiapedesis[16,17].Thesesteps
are mediated by surface adhesion molecules and cytokines
on both leukocytes and BEC and the avidity of interactions
among diﬀerent intercellular interacting molecular pairs.
The initial low-aﬃnity contacts, leading to tethering and
rolling, slow down the ﬂowing leukocytes and are mediated
by the binding of selectins on the glycocalyx of BEC to
their paired ligands on leukocytes. Firm adhesion (arrest) of
the leukocytes is mediated by the binding of cell adhesion
molecules (CAMs) on EC to their respective integrins on
the leukocyte surface. ICAM1 and VCAM1 are two well-
knownCAMsthatareoverexpressed onbrainECinresponse
to inﬂammatory insults. ICAM1 can pair with either αLβ2
(LFA1, CD11a/CD18) or αMβ2 (Mac1, CD11b/CD18) inte-
grins, while VCAM1 interacts with α4β1 (VLA4, CD49d/
CD29) integrin on leukocytes [18].
Leukocyte diapedesis from the luminal surface of BEC
to its abluminal side is the last step in the transmigration
process and is the least well understood. The step has been
traditionally believed to take place through the paracellular
route, that is, through the TJ of BEC [19]. A number of
intercellular interacting pairs (IIPs), including JAM1-JAM1,
JAM1-LFA1, PECAM1-PECAM1, and CD99-CD99, have
been identiﬁed between BEC TJ and leukocytes [20]. How-
ever, the paracellular migration route has been repeatedly
challenged by histological and electron microscopy studies
demonstrating that leukocytes can migrate through the
transcellular pathway, that is through the BEC themselves,
leaving the TJ morphologically intact [17, 18, 21]. While it
is likely that the leukocyte migration occurs through both
pathways [17], the details of the molecular events involved
in either of the pathways remain limited.
3.Therapiesagainst LeukocyteMigration
into the Brain: Successesand Failures
Inhibiting the interactions between the migrating leukocytes
andtheBECisanattractivetherapeuticapproachforinhibit-
ing tissue inﬂammation. A target is usually a molecule that is
essential in thetransmigration process and is easily accessible
to therapy. The IIPs discussed above are some of the key
players in diﬀerent stages of the leukocyte transmigration
process and are also blood-accessible molecules, that is,
present on either the surface of leukocytes or the luminal
membranes of BEC. Blocking antibodies against the selected
leukocyte-brain BEC IIPs have already been developed and
used in preclinical studies and clinical trials.
Two IIPs have been primarily targeted for the inhibi-
tion of CNS inﬂammation: VCAM1-VLA4 interactions or
ICAM1-LFA1 interactions. Blocking antibodies and other
drug molecules against the α4-integrin part of VLA4 have
been shown to inhibit or reverse the EAE in various
animal models (summarized in [18]). These ﬁndings led
to the development of a humanized monoclonal anti-α4-
integrin antibody, Natalizumab, which was evaluated in
two randomized, double-blind, placebo-controlled trials in
patients with multiple sclerosis. The results of the trials
demonstratedalargebeneﬁtforpatientstakingNatalizumab,
including a 42% reduction in the risk of sustained disability
progression and a 68% reduction in relapse rate [22].
The drug was initially approved by FDA in 2004, but was
subsequently withdrawn after it was linked with few cases
of progressive multifocal leukoencephalopathy (PML) when
combined with immunomodulatory treatment [22, 23].
However, after a review of safety information, the drug was
returned to the market in 2006 because its clinical beneﬁts
outweighed the risks involved. While Natalizumab has
proven to be very successful in controlling the disease, some
limitations due to side eﬀects have been reported, including
elevated lymphocyte, basophil, and eosinophil counts, with
5%ofdrugrecipientsshowing circulatingnucleatederythro-
cytes [23]; these side eﬀects are likely due to widespread
functions of α4 integrin in the hematopoietic system
[18, 23].
Blocking antibody therapies targeting ICAM1 and LFA1
have also been developed. In vitro studies using these
antibodies have consistently shown that the ICAM1-LFA1
interaction is important for T-cell adhesion and diapedesis
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these therapies have produced highly conﬂicting results
in CNS inﬂammation in vivo. While some studies have
shown a beneﬁcial outcome of blocking either ICAM1 or
LFA1, others could not ﬁnd a signiﬁcant inhibition or even
showed worsening of the outcome and early mortality in
the EAE animal models [18, 24]. Furthermore, clinical trails
using humanized anti-LFA1 (Rovelizumab, LeukArrest) and
anti-ICAM1 (Enlimomab) antibodies have shown lack of
eﬃcacy or serious side eﬀects. Another anti-VLA1 antibody
(Efalizumab) has been approved for the therapy of psoriasis,
a non-CNS inﬂammatory disorder [25]. Thus, while the
role of ICAM1-LFA1 interaction is controversial in CNS
inﬂammation, this interaction plays an important role
(similar to VCAM1-VLA4 interaction) in peripheral, non-
CNS inﬂammation.
4.Unmet Needs and theHypothesis
4.1. Discovery of Novel, Speciﬁc Targets. Currently, only a
limited number of molecules on leukocytes and the BBB
are known or known to interact. For example, ICAM1-LFA1
and VCAM1-VLA4 pairs have been known for more than
two decades and are still pursued as the main targets for
inhibiting interactions between endothelium and leukocytes
in the brain. Targeting these interactions alone does not
provide complete protection, suggesting that other adhesion
molecules may “compensate” when these interactions are
blocked [26]. From problems associated with the functional
redundancy of leukocyte-BEC molecular interactions and
the inhibition of peripheral immune system function with
current treatments, an important need has emerged to
discover molecules speciﬁcally involved in the adhesion
and diapedesis of speciﬁc subsets of leukocytes through
the BBB that are less important in the overall immune
system competency. With emerging evidence of the role of
the IL-23-induced IL-17-producing T cells in the patho-
genesis of multiple sclerosis and cerebral ischemia, there
is a need for identiﬁcation of more speciﬁc molecules
on these subpopulations of leukocytes, which confer their
brain-tropism, to develop more cell-selective targets. Fur-
ther, there is a need to identify cell-speciﬁc (and human-
speciﬁc) molecules as targets on brain EC to minimize non-
speciﬁc side eﬀects of current drugs (described above). We
propose that human brain EC and human brain tropic
T-cells should become key models to discover novel tar-
gets implicated in neuroinﬂammatory cell recruitment and
migration.
5.Hypothesis
Using advanced methods that combine membrane and
submembrane proteomics and glycoproteomics with meth-
ods of in silico interactomics, a novel set of intercel-
lular interactions between human brain endothelial cells
and human CNS-homing T cells, can be identiﬁed and
exploited as therapeutic targets for preventing brain inﬂam-
mation caused by recruitment of peripheral inﬂammatory
cells.
6.Testing theHypothesis
The ﬂow chart of proposed strategy to test the above
hypothesis is shown in Figure 1.T h eﬁrst phase of the
strategy includes the development of appropriate methods
for membrane and submembrane proteomics and glyco-
proteomics and appropriate model system(s) for testing
the hypothesis, including the generation and curation of
database(s) of relevant known protein-protein and protein-
carbohydrate interactions. The second phase involves the
application of membrane and submembrane proteomic
methods to the selected model system to identify protein
and glycoprotein changes induced in endothelial cells and
CNS-tropiclymphocytes underpathological conditions(i.e.,
inﬂammation or ischemia). In the third phase,i n t e r c e l l u l a r
interacting pairs (IIPs) between brain BEC and CNS-tropic
lymphocytes, with potential roles in leukocyte-endothelium
contact or communication (i.e., interactions among secreted
proteins and cell surface proteins), are identiﬁed using in
silico interactomics.Finally,validationoftheroleofidentiﬁed
IIPs in leukocyte adhesion/transmigration is accomplished
using in vitro assays and biological readouts. Elements and
phases of this strategy, and preliminary results obtained in
method and approach development, are described in detail
below.
6.1. Phase 1: Development and Validation of Methods
6.1.1. Membrane and Submembrane Proteomics Methods.
Proteins present on cell membranes, facing the extracellular
environment, are the main site of contacts between BEC
and leukocytes during adhesion and diapedesis. The contact
site on BEC is mainly the luminal membrane (glycocalyx),
which consists of a complex mixture of proteins, glyco-
proteins, and other molecules. Since BEC have “polarized”
membranes, that is, moleculeson the luminal and abluminal
membranes are diﬀerent, there is also a need to couple
submembrane fractionation with proteomics to identify
the diﬀerences between the various fractions. Analyzing
membrane molecules has usually been diﬃcult, especially
using proteomics. Traditional 2Dgel-based proteomicmeth-
ods lack the sensitivity, reproducibility, and the ability to
analyze the complete spectrum of membrane proteins, due
to inherent limitation of the technology (summarized in
[27]). A quantitative and reproducible method for analyzing
glycosylated proteins on a global scale has been lacking.
Over the last 5 years, technological growth in the
proteomics ﬁeld has led to the development of advanced
nanoLC-MS-based systems that are composed of highly
reproducible and sensitive nanoﬂow ultra HPLC systems
(e.g., nanoAquity), coupled with sensitive and high mass-
accuracy MS instruments (e.g., Orbitrap) [28]. We and oth-
ers have also developed bioinformatics software that analyze
nanoLC-MS data, allowing the quantiﬁcation of thousands
of proteins and glycoproteins in multiple biological samples
[29]. In addition, the recent development of hydrazide
capturetechnology [30, 31]hasenabledselective enrichment
of glycoproteins from cells and tissues for large-scale iden-
tiﬁcation, using nanoLC-MS-based quantitative proteomics.4 Cardiovascular Psychiatry and Neurology
Phase 1: method development
Phase 2: experimental approach
Phase 3: in silico interactomics of HBEC and T17 lymphocytes
Phase 4: target validation
Luminal/abluminal
membrane separation
Membrane and secreted
proteomics and
glycoproteomics
Development and
curation of interactomics
database(s)
Create brain endothelial cell
data set of membrane and
secreted (glyco) proteome
Create T17 lymphocyte data
set of membrane and secreted
(glyco)proteome
Identify putative IIPs involved in
cell-cell contact from
interactomics database(s)
Identify putative IIPs involved in
cell-cell communication from
interactomics database(s)
Select IIPs from phase 3 that can be targeted therapeutically
Raise antibodies against selected IIPs (or their domains)
Validate the role of IIPs by showing that antibod(ies) block
relevant cell-cell interactions (adhesion, transmigration)
Optimize blocking antibodies as therapeutic leads
Figure 1: Schematic ﬂowchart of the proposed approach to identify protein-protein interactions between Th17 lymphocytes and brain
endothelial cells that are functionally implicated in the recruitment of inﬂammatory/immunecells across the blood-brain barrier.
Recently, we also described methods to enrich for various
membrane fractions (e.g., luminal, abluminal) from human
BECand othercells, and coupledthis with hydrazide capture
and quantitative nanoLC-MS-based proteomics [28, 30].
This combination of submembrane isolation methods and
advanced proteomics and glycoproteomics technology is
needed to discover novel proteins and glycoproteins on the
surfaces of BEC and T cells.
6.1.2. Intercellular Interactomics Data Base(s). Proteomics
and other genomics methods generate overwhelming data
sets of molecules that become diﬃcult to follow up. Since
validating entire “lists” becomes costly and time consuming,
a single-factor/reductionist approach is often undertaken to
select (or “cherry pick”) a couple of molecules for further
evaluation. As a result, a signiﬁcant portion of disease-
implicated molecules are simply overlooked. Thus, there
is a need for development and application of alternative
methodology to identify the overlooked molecules, which
may includenovel and more speciﬁc targets. Systemsbiology
is the ﬁeld of biology that aims to provide a more “holistic”
view by examining the network of interactions between
multiplemolecules, pathways,cells, andcharacteristics ofthe
tissue, as they converge to determine the disease implication
of the molecules [32]. Since molecular interactions are the
fundamentalsofsystemsbiology,alargeamountofeﬀorthas
been invested into generating protein-interaction databases
through large-scale experimental interactomics and curation
ofthescientiﬁc literature[33].Wepropose touse thecurated
protein-protein interaction databases and systems biology
approaches, to identify which molecules actually interact
between BEC and brain-speciﬁc lymphocytes. This in silico
interactomics methodology has a potential to identify novel
I I P sa st h e r a p e u t i ct a r g e t sf o rC N Si n ﬂ a m m a t i o n .
Protein interactions have traditionally been measured
using immunoprecipitation and yeast two-hybrid systems.
However, high-throughput techniques have also been devel-
oped that identify aﬃnity pull-down complexes using
advanced proteomics [34], and systematically constructed
double-knockout strains in yeast have proven to be useful
for constructing a large-scale view of molecular interaction
networks [35]. As a result, a number of publicly available
protein-protein interaction databases currently exist, includ-
ing BIND, Human Protein Reference Database, HiMAP,
BioGRID, and EcoCyc. Utilizing these existing databases and
datasets, wereconstructedan in-house databaseconsisting of
more than a million molecular interactions. For the current
study, we limited the interactions to immunoprecipitationCardiovascular Psychiatry and Neurology 5
and aﬃnity pull-down assays in mammalian systems to
reduce the incidence of false interactions. The resulting
mammalian protein-protein interaction database (mPPI-db)
consists of more than 200,000 nonredundant interactions,
and was used for the discovery of novel IIPs between human
brain endothelial cells (BEC) and lymphocytes using the
experimental approaches described below.
6.2. Phase 2: Experimental Models and Their Validation
6.2.1. Activated Human BEC. Brain endothelium under-
goes signiﬁcant changes in response to inﬂammation and
becomes more receptive to interactions towards immune
cells. This “activation” of the endothelium is characterized
by molecular and physical changes in the luminal glycocalyx.
Because proposed studies are focused on BEC-lymphocyte
interactions relevant for human disease, to test the hypoth-
esis we used the hCMEC/D3 human brain endothelial cell
line as a stable human in vitro model of the BBB [36]. The
cells were grown in EBM-2 media (Lonza, Walkersville, MD)
supplementedwith2%FBSand wereactivated underserum-
free conditions using various inﬂammatory insults, includ-
ing TNFα/INFγ,I L - 1 β, or simulated ischemia/reperfusion
conditions as previously described [26, 37, 38]. Although
lymphocyte transmigration process in vivo occurs in post-
capillary venules, there are currently no in vitro BBB models
that speciﬁcally distinguish endothelium from capillaries
and venules; most models, including the one used in these
studies are mixed population of endothelial cells originating
from both. The hCMEC/D3 have been demonstrated to
be valid for studies of BBB function, responses of brain
endothelium to inﬂammatory and infectious stimuli, and
the interaction of brain endothelium with lymphocytes or
other cells [26, 36]. From the activated cells, proteins from
luminal (apical) and abluminal (basolateral) membranes
and from cellular and secreted fractions were isolated using
recently described methods [28], enriched for glycoproteins
using hydrazide capture [30], and analyzed using nanoLC-
MS-based quantitative proteomics to identify diﬀerentially
expressed molecules [39]. In total, more than 4500 unique
proteins and glycoproteins were identiﬁed in the human
BEC, with about 650 present on each the luminal and
abluminal membranes. In addition, about 25–30% of all
the proteins responded signiﬁcantly to the inﬂammatory
insults, several of which were well-known indicators of BEC
activation. Upregulation of surface adhesion molecules on
luminal membranes (including ICAM1, VCAM1) changes
in several TJ proteins [19] and integrins, including β1, β2,
α4, αL, αM were observed. A number of proteins involved
in intracellular signaling and downstream pathways were
also detected, including those involved in the recruitment
of the “transmigratory cup” machinery [20]t ot h el u m i n a l
membranes, for example, ezrin, moesin, radixin, and other
cytoskeletal proteins, suggesting that the cells have been
“primed” for the anticipated process of leukocyte adhesion.
Furthermore, about 20% of the proteins were associated
with BEC-alone or BEC activation as found by large-scale
literature mining. These results validate adequate activation
of hCMEC/D3 cells with inﬂammatory insults and suggest
the validity of the model for further discovery of BEC-Th17
IIPs.
The majority of the cellular, membrane, and secreted
proteins identiﬁed (>75%) were not previously described
to be associated with BEC, BBB, luminal or abluminal
membranes, CNS inﬂammation or leukocyte traﬃcking; 50
of these molecules were surface adhesion molecules that
have not been previously reported in BEC in response to
inﬂammation. Thus, the use of advanced proteomic and
glycoproteomic tools led to identiﬁcation of a large number
of novel molecules in the luminal glycocalyx and other
cellular compartments of human BEC.
6.2.2. Brain-Homing T Cells. The same advanced tools were
also utilized to discover novel molecules in leukocytes.
T cells with encephalo-tropism were generated by activation
of lymphocytes, isolated from multiple sclerosis patients,
with IL-23 as recently described [7]. These IL-17-producing
T-helper (i.e., Th17) cells were utilized for further analysis,
which included isolation of cellular and secreted proteins
and performing label-free proteomics/glycoproteomics to
identify molecular changes. More than 2850 cellular, 1875
membrane and 450 secreted proteins and glyoproteins were
identiﬁed in the IL-23-activated Th17 cells. These included
the key glycoproteins IL-17, IL-22, INFγ,a n dT N F α in
the secreted fraction, validating the adequate activation of
the cells. Well-known membrane glycoproteins involved in
endothelium adhesion, such as LFA1, Mac1, and VLA4, were
also detected in the activated Th17 cells. Furthermore, a
number of proteins involved in intracellular signaling and
downstream pathwayswere alsoidentiﬁed,includingpaxilin,
talin, vinculin, Arp2/3, wasp, and cytoskeletalproteins. Since
theseproteinsareinvolvedincellmigrationandprojection—
including formation of podosome-like structures for
invasion—the Th17 cells appear to be primed for the antic-
ipated attachment, adhesion, and diapedesis process. The
majority of the molecules (>80%) identiﬁed in the activated
Th17 cells (in both membrane and secreted fractions)
were not described in the literature in association with T
lymphocytes, inﬂammation, or leukocyte traﬃcking. These
newly Th17-associated molecules include 10 additional
integrins and more than 200 additional adhesion molecules,
suggesting the potential importance of new molecular
interactions and interacting pairs between Th17 and BEC.
The summary of the experimental approach used to
generate membrane and secreted proteome data sets from
human BEC and brain-tropic Th17 lymphocytes is shown in
Figure 2.
6.3. Phase 3: Constructing Intercellular Networks between
hBEC and T Cells. A computational approach was under-
taken to construct intercellular interaction networks of
stimuli-responsive molecules identiﬁed in human BEC and
Th17 cells. This involved searching for each protein-protein
interaction from the mPPI-db in the two proteomic datasets,
such that one interactant is in the BEC and the other in the
Th17 dataset. The resulting network consisted of more than
9000 interactions and was referred to as the master IIP net-
work, since it represented all possible IIPs between the two6 Cardiovascular Psychiatry and Neurology
hCMEC/D3 cells
Activation by inﬂammatory insults
(versus nonactivated controls)
Cellular, secreted,and membrane
(apical/basolateral) protein isolation
NanoLC-MS-based proteomics
and glycoproteomics
HBEC data set
Intercellular interactomics
Novel therapeutic targets
Th17 lymphocytes from
multiple sclerosis patients
Activation by IL-23 to induce CNS tropism
(versus nonactivated controls)
Cellular and secreted protein isolation
NanoLC-MS-based proteomics
and glycoproteomics
Th17 data set
Figure 2: Schematic representation of the experimental approach used for described studies. Immortalized human brain endothelial cell
line, hCMEC/D3 was exposed to various inﬂammatory cytokines or oxygen-glucose deprivation to identify diﬀerentially expressed proteins
in response to these stimuli in luminal and abluminal membranes as well as in secreted proteins. Th17 lymphocytes derived from MS
patients were exposed in vitro t oI L - 2 3t oi n d u c et h e i rC N St r o p i s ma n dt oi d e n t i f yp r o t e ins regulated by this treatment. Respective databases
of regulated proteins in inﬂammation-primed brain endothelial cells (BEC) and CNS-tropic Th17 lymphocytes were subjected to in sillico
interactomics analysesto mapputative protein-protein interactionsthatmaycontribute to Th17cell adhesionandtransmigrationacross the
blood-brain barrier (BBB).
datasets. However, most of these IIPs are unlikely to occur
in vivo, since the intercellular pathological and physiological
interactions and communications between T cells and BEC
are limited to only accessible molecules, that is, surface and
secreted molecules. To reduce the complexity of the master
networkandidentifymorerelevantIIPs, welimitedtheinter-
actions to cell-cell “contacts”a n d“ communications.”T h e
intercellular “contacts” consist of interactions between BEC
and Th17 surface molecules, whereas intercellular “com-
munications” consist of interactions between BEC secreted
and Th17 surface molecules, and vice versa. For surface
molecules, only proteins containing extracellular membrane
domains were included. Furthermore, only molecules that
were expressed under activated conditions were included.
These criteria signiﬁcantly reduced the master IIP network
and produced a more relevant network of cell-cell contacts
(Figure 3) and communications (Figure 4) between T cells
and brain endothelium during leukocyte traﬃcking.
6.4. Identiﬁcation of Novel IIPs between
Human BEC and T Cells
6.4.1. Cell-Cell Contacts. A network of cell-cell contact
points between human BEC and Th17 cells was generated
to identify potential IIPs involved in the adhesion and dia-
pedesis processes (Figure 3).The network showsinteractions
between molecules on membranes of Th17 with molecules
on either luminal membranes or in the TJ of BEC. In
addition,itshowsthemoleculesontheabluminalmembrane
of BEC that can interact with Th17 surface molecules. It
is apparent from the network (Figure 3)t h a tm a n ym o r e
IIPs are identiﬁed than there are currently known in the
literature. Great number of molecules showed a high degree
of interactions, that is, they interacted with more than one
protein and with as many as 18 proteins. If accurate, these
results suggest that interactions between T cells and the
glycocalyx of endothelium are likely much more complex,
involving a signiﬁcantly larger number of molecules than
previously believed.
More than 180 interacting pairs (IIPs) were detected
between 116 Th17 membrane proteins and 62 human BEC
glycocalyx proteins. About half of the molecules (55%) have
beenpreviouslyassociated intheliteraturewith endothelium
or T-lymphocytes in general, but very few have been
implicated speciﬁcally with either BBB, Th17 cells, or BEC-
T cell adhesion/diapedesis. This suggests that many of the
molecular changes in brain endothelium in response to
inﬂammation are commonwith changesin otherendothelia,
and similar is true for Th17 and T cells. Some of identiﬁed
IIPs between human BEC glycocalyx and Th17 membranes
included VCAM1-VLA4, ICAM1-LFA1, ICAM1-Mac1, P-
selectin-PSGL1, and E-selectin-ESL1, respectively (Figure 3,
table insert). Most of the molecules involved in these IIPs
had high number ofintercellularinteractions in thenetwork.
While connection points or “nodes” like these with high
numbers of interactions in the network can potentially
be used to locate potential targets to interrupt interaction
between cells, more often they indicate very common,
redundant, or nonselective interactions and consequently
may lead to drug side eﬀects [40]. The network however
s u g g e s t st h a tt h er e m a i n i n gI I P sa r en o v e la n dp e r h a p sm o r e
speciﬁc to human BEC-Th17 interactions.Cardiovascular Psychiatry and Neurology 7
BEC luminal or TJ membrane proteins
that can interact with Th17 proteins
BEC abluminal membrane proteins that can
interact with Th17 membrane proteins
Th17
TJ
Luminal
Abluminal
BEC
Nodes Degree Examples of intercellular
interactions
Th17 membranes VLA4 12 VCAM1
LFA1 CAM1, JAM1
Mac1 CAM1
PECAM1 2
2
2
PECAM1
CD99 1 CD99
JAM1 1 JAM1
PSGL1 1 E-selectin
BEC luminal membranes ICAM1 LFA1, Mac1
VCAM1 2
7
VLA4
ALCAM 1 CD6
E-selectin 1 ESL1
P-selectin 1 PSGL1
BEC TJ membranes JAM1 2 JAM1
PECAM1 1 PECAM1
CD99 1 CD99
Noninteracting membrane proteins
Th17 membrane proteins that can interact
with BEC secreted proteins
Figure 3: Shown is a visual depiction of the intercellular interaction network between proteins identiﬁed in Th17 lymphocytes and
hCMEC/D3 brain endothelial cells using approach described in Figure 2. Each identiﬁed protein is represented by an oval; noninteracting
proteins are shown in white, membrane proteins identiﬁed in Th17 lymphocytes that can interact with luminal membrane proteins of brain
endothelial cells (BEC) are shown in blue, BEC luminal membrane- and tight junction proteins that can interact with Th17 membrane
proteins are shown in red, and BEC abluminal proteins that can interact with Th17 membrane proteins are shown in green. Proteins were
identiﬁed using membrane and subcellular proteomics and glycoproteomics and their interactions were catalogued using protein-protein
databases as described in the text (each interaction is shown as a line connecting interacting proteins). Insert: the table shows a listof known
proteins identiﬁed from the interactome network. Nodes represent the proteins or connection points in the membranes of Th17 and BEC
in the network, and degree is the number of intercellular connections per node. Examples of these intercellular interactions are shown in the
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Noninteracting membrane proteins
Th17 membrane proteins that can interact
with BEC secreted proteins
BEC luminal membrane proteins that can
interact with Th17 secreted proteins
Th17 secreted proteins that can interact
with BEC membrane proteins
BEC secreted proteins that can interact
with Th17 membrane proteins
HBEC Luminal
Th17
Figure 4: Extracellular signaling (communication) between Th17 and BEC. Shown is a visual depiction of the intercellular interaction
network between proteins secreted by either Th17 lymphocytes or BEC and their interacting membrane counterparts expressed on the
other cell type. All identiﬁed membrane proteins are represented by ovals, whereas secreted proteins are represented as circles: in red are
luminal BEC membrane proteins that interact with secreted T17 proteins (in blue circles); in blue are membrane T17 proteins that interact
with secreted BEC proteins (in red circles). Proteins were identiﬁed using membrane and subcellular proteomics and glycoproteomics and
their interactions were catalogued using protein-protein databases as described in the text (each interaction is shown as a line connecting
interacting proteins).
Not unexpectedly, IIPs between human BEC TJs and
Th17 membranes were also discovered (Figure 3), consistent
with the postulated mechanisms of leukocyte diapedesis.
During the paracellular diapedesis process, leukocytes may
encounter homophilic interactions with TJ molecules, cre-
ating zipper-like contacts that replace the interendothelial
junction [18]. Corroborating this and further validating the
generated interactome network, we detected the known IIPs
JAM1-LFA1, JAM1-JAM1, PECAM1-PECAM1, and CD99-
CD99 pairs between the BEC TJs and the Th17 membranes,
respectively. More than 50 additional IIPs between TJs and
Th17 membranes were also identiﬁed, many of which have
not been previously associated in this context.
Finally, 113 IIPs between human BEC abluminal mem-
branes and Th17 membranes were also identiﬁed (Figure 3).
T h e s ea r eo fs i g n i ﬁ c a n c es i n c et h e ym i g h tb ei n v o l v e di n
the diapedesis process through the transcellular pathway. In
the ﬁnal stages of this process, the transmigrating leukocytes
need to transverse the abluminal membrane to enter the
perivascular space and thus may recruit these IIPs.Cardiovascular Psychiatry and Neurology 9
Taken together, the cell-cell contact network provides
new insights into the complexity of the adhesion and
diapedesis processes and underscores that the intercellular
interactions involved are likely not limited to just a few well-
known IIPs, but rather extend to dozens of well-organized,
cell-domain-localized molecular interactions.
6.4.2. Cell-Cell Communication. A network of cell-cell
paracrine communications between human BEC and Th17
cells was also generated (Figure 4)t oi d e n t i f ye x t r a c e l -
lular signals potentially involved in the cross-talks dur-
ing leukocyte recruitment, adhesion, and diapedesis. The
network shows the signals released from one cell which
interact with their known receptors on the other cell’s
surface (Figure 4), depicting the potential cross-talk between
leukocytes and the BBB during inﬂammation. Most of the
signaling molecules identiﬁed were cytokines, chemokines,
hormones, and/or growth factors. While the majority of the
paracrine signaling molecules were not previously associ-
ated in the literature with leukocyte-BBB communication,
several expected interacting pairs were also detected. These
included MCP1, RANTES, and CCL19 cytokines in the
BEC secretome and their respective receptors on the Th17
surface. Likewise, IL17, IL22, and others were detected in
the Th17 secreted milieu and their receptors on the BEC
glycocalyx. More than 25 additional extracellular signaling
molecules from BEC were found to have receptors on Th17.
Some of these receptors are known to be involved in T-
cell recruitment/activationduring theprocess oftransmigra-
tion. Furthermore, more than 30 signals from Th17 were
found to have receptors on human BEC, some of which
are involved in receptor-mediated endocytosis/transcytosis.
Overall, it was apparent that the paracrine communication
between leukocytes and BBB under inﬂammatory condi-
tions involves a large number of complex soluble ligand-
receptor interactions which might lead to “priming” of the
receptive cell for the anticipated diapedesis/transmigration
process.
6.5. Phase 4: Validation of IIPs That Can Be Targeted Thera-
peutically. Validation of human BEC-T17 IIPs that may
be suitable for the development of (blocking) therapeu-
tic approaches could be done using various approaches.
We propose that, after selection of potentially important
interactions based on various bioinformatics algorithms
that determine “strengths” of interactions in silico, poten-
tially “drugable” interactions could be identiﬁed based on
predetermined set of criteria including target molecule
expression in brain vessels in vivo,accessibility from systemic
compartment, brain/disease speciﬁcity, and so forth. In
previous studies that compared the expression of proteins
identiﬁed by 2D-gel and ICAT proteomics in BBB model(s)
in vitro [38] and those identiﬁed using ICAT proteomics
in laser-captured microvessels from animals in vivo [41],
we identiﬁed and validated using immunochemistry and
enzyme assays 19 commonly expressed proteins. In another
proteomics study that identiﬁed more than 40 lipid-raft-
speciﬁc proteins in human BEC in vitro, the expression
of majority of these proteins has been conﬁrmed in brain
vessels in human brain tissue sections in vivo [26, 42, 43].
Most notably, activated leukocyte cell adhesion molecule
(ALCAM) identiﬁed in these studies has been shown to
promote leukocyte traﬃcking across the BBB through
homotypic interaction with leukocytes; inhibition of this
interaction reduced the severity and delayed the time of
onset of experimental autoimmune encephalomyelitis in
animal model. These studies provide validation that some of
identiﬁed BEC-Th17 cell-cell interactions could be success-
fully targeted in vivo to inhibit leukocyte migration across
the BBB.
The systematic validation of the role of BEC-Th17 cell-
cell interactions catalogued by methods described above
in facilitating leukocyte transmigration could be achieved
using a high-throughput antibody development approach
that targets the relevant epitopes of interacting molecules.
For example, this can be done using antibody display
approaches (phage or ribosome display) or in vivo immu-
nization against expressed epitopes of interacting molecules.
Resulting antibody “libraries” could then be screened for
antibodies with interaction blocking properties using var-
ious in vitro assays (Surface Plasmon Resonance—SPR,
ELISA etc.) or biological readouts that determine biological
functions of the antibodies, for example, an eﬃcacy in
inhibiting leukocyte adhesion to brain endothelial cells
or leukocyte transmigration across in vitro BBB mod-
els. Antibodies eﬃcacious in modulating and inhibiting
leukocyte adhesion and transmigration across the in vitro
BBB model simultaneously validate the physiological or
pathological role of identiﬁed IIPs. Identiﬁed “function-
blocking” antibodies in vitro, could proceed into testing
in various animal models, including EAE model [26]. The
resulting lead molecule(s) could become amenable for fur-
ther development as diagnostic, therapeutic, or theranostic
for the treatment of neurological conditions accompanied,
or caused by, leukocyte/lymphocyte inﬁltration. As a proof
of concept for such an approach, we have generated a library
of anti-ICAM-1 single-domain (VhH) antibodies from an
immunized llama phage-displayed library, among which two
antibodies displayed high aﬃnity and ICAM-1 blocking
activity in leukocyte adhesion assays (unpublished). One of
these antibodies is currently being developed as molecular
imagingagentforvascularinﬂammatory activationinstroke.
Current advances in antibody engineering enable generation
of bispeciﬁc antibodies that could simultaneously target
more than one interacting molecule involved in the process
of T-cell brain entry.
The proof of concept for clinical translation of proposed
approach has already been achieved with Natalizumab anti-
body, showing that the inhibition of leukocyte recruitment
into the brain by antibody that blocks one of molecu-
lar interactions between leukocytes and BEC resulted in
clinically successful control of inﬂammatory brain disease.
The hypothesis and experimental approach described in
this paper provide the opportunity to identify and clin-
ically target other important leukocyte-BEC interactions
that are more speciﬁc/selective for brain-tropic leukocyte
subsets.10 Cardiovascular Psychiatry and Neurology
7.Conclusions
To develop new therapies for inhibiting CNS inﬂammation,
there is a need to identify novel interacting molecules
between CNS-homing T cells and activated BEC. Currently
only a limited number of molecules on leukocytes and BEC
are known or known to interact. We have hypothesized
here, and have been successful in demonstrating, that inter-
acting molecules of potential therapeutic signiﬁcance can
be discovered through the combination of advanced mem-
brane/submembrane proteomic and interactomic methods.
A number of novel protein-protein interactions identiﬁed
between BEC luminal and Th17 membrane molecules by
these methods are key targets for inhibiting various stages
of T-cell entry into brain, including T cell/BEC attachment,
ﬁrm adhesion, and diapedesis. In addition, formation of
specialized domain, including recruitment of the “transmi-
gratory cup” complex at luminal membranes in BEC and
evidence of podosome-associated molecules on the activated
T cells, not only suggests that the cells are preparing and
ready for interactions, but also identiﬁes these structures
as important therapeutic targets. Furthermore, interactions
identiﬁed between BEC tight junction and Th17 membrane
molecules are key therapeutic targets for inhibiting the
paracellular diapedesis route. The identiﬁed TJ molecules
may also be involved in the transcellular process since
Muller and coworkers recently showed that the membrane
from a parajunctional reticulum of interconnected vesicles,
containing JAM1, PECAM1, and CD99, is recruited to
surround the transcellularly migrating leukocytes and aids
in the process [44]. Interactions identiﬁed between BEC
abluminal and Th17 membrane molecules are also inter-
esting as therapeutic targets since they may be involved in
the ﬁnal stages of the diapedesis process (by either route).
Finally, intercellular paracrine signaling between T cells and
BEC is also considered an important target for inhibiting
recruitment and activation of the leukocytes. Collectively,
identiﬁcation of novel human BEC-Th17 IIPs not only
allows more in-depth understanding of the interactions and
communications between CNS-homing T cells and activated
BEC, but also allows discovery of novel targets for therapy at
diﬀerent stages of the CNS inﬂammation.
The combination of advanced methodologies described
here also has other applications. The use of emerging
membrane/submembrane proteomic and glycoproteomic
methods is applicable to other systems to allow identiﬁca-
tion of blood-accessible luminal and secreted targets. The
intercellular interactomics has applications in understanding
the complex interactions and communications among the
various cell types in other systems.
The signiﬁcance of the molecules discovered by the
advanced “omic” methodologies described here also goes
beyond the scope of this hypothesis. Novel molecules
identiﬁed on the luminal surfaces of the activated BEC are
also attractive targets for molecular imaging-based diagnosis
of inﬂammatory insults in the brain since they are blood-
accessible. Molecules identiﬁed in IL-23 stimulated Th17
cells may clarify the mechanism of tropism of these cells
toward the CNS. Furthermore, secreted signaling molecules
from BEC and T cells also target other cell types, including
cells in the neurovascular unit, as well as in the peripheral
tissues. It would be interesting to further elaborate these
intercellular networks to decipher the complex communica-
tions within the CNS, as well as between the CNS and the
peripheral environment.
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